Cited by 674Protein Degradation and InhibitorsChemical Synthesis and AnalysisUbiquitin and proteasome pathways

Small‐Molecule PROTACS: New Approaches to Protein Degradation

Toure, Momar, Crews, Craig M.·2016·Angewandte Chemie International Edition

Abstract

The current inhibitor‐based approach to therapeutics has inherent limitations owing to its occupancy‐based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off‐target side effects, and 3) there is a need to bind to an active site, thus limiting the drug target space. As an alternative, induced protein degradation lacks these limitations. Based on an event‐driven model, this approach offers a novel catalytic mechanism to irreversibly inhibit protein function by targeting protein destruction through recruitment to the cellular quality control machinery. Prior protein degrading strategies have lacked therapeutic potential. However, recent reports of small‐molecule‐based proteolysis‐targeting chimeras (PROTACs) have demonstrated that this technology can effectively decrease the cellular levels of several protein classes.

Integrity signals

Registry

Crossref · 10.1002/anie.201507978

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Toure, M., & Crews, C. M.
Affiliations
Yale University (US)
Corresponding author
Crews, Craig M.
Venue
Angewandte Chemie International Edition
Publisher
Wiley
Published
2016-01-12
Volume
55
Issue
6
Pages
1966-1973
ISSN
  • 1433-7851 (ISSN-L)
  • 1521-3773
OpenAlex
W2237051895
Cited by
674
References
68
Citations by year
2026: 54 · 2025: 69 · 2024: 81 · 2023: 59 · 2022: 82 · 2021: 71 · 2020: 82 · 2019: 66 · 2018: 40 · 2017: 46 · 2016: 24
FWCI
5.30
Type
journal article
Language
en
Open access
closed
Locations
  • Angewandte Chemie International Edition (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Leukemia & Lymphoma Society
  • NIH (R35A197589, R01AI084140)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chemical Synthesis and Analysis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords
PROTACs, protein degradation, cell quality control, off-target effects
MeSH terms
Proteins, Small Molecule Libraries, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review